Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aptorum Group Ltd - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
APM
Nasdaq
2834
http://www.aptorumgroup.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aptorum Group Ltd
Aptorum Group Limited Announces Results of 2019 Annual General Meeting
- Nov 15th, 2019 1:00 pm
Aptorum Group Limited's (NASDAQ:APM) Single Biggest Risk For Investors
- Sep 19th, 2019 12:10 pm
APM: Aptorum Focused on Development of Diseases with Significant Global Unmet Needs
- Jun 26th, 2019 3:05 pm
Aptorum Group to Be Newly Added to MSCI HK Micro Cap Index
- May 22nd, 2019 12:00 pm
Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co-Working Laboratory Ecosystems for Life Sciences Start-Ups in the United States
- May 16th, 2019 1:00 am
What Percentage Of Aptorum Group Limited (NASDAQ:APM) Shares Do Insiders Own?
- May 7th, 2019 11:19 am
Aptorum Group’s Subsidiary - Claves Life Sciences Limited Establishes Novel Therapeutic Platform for Treatment of Various Diseases via Modulation of the Chemical Signaling Relating to Gut Microbiota
- May 6th, 2019 12:00 pm
UPDATE - Argus Research Initiates Equity Research Report Coverage on Aptorum Group Limited (NasdaqGM: APM)
- Apr 30th, 2019 2:42 pm
USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations
- Apr 24th, 2019 12:00 pm
Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™
- Apr 24th, 2019 8:30 am
Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases
- Apr 24th, 2019 8:30 am
Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 2019
- Apr 24th, 2019 8:15 am
Aptorum Group Limited Reports 2018 Fiscal Year Financial Results and Business Update
- Apr 15th, 2019 1:55 pm
Aptorum Group Limited Announces Appointment of Head of R&D and Chief Operating Officer
- Apr 1st, 2019 1:30 pm
Aptorum Group Limited to Present at the Barclays Global Healthcare Conference 2019
- Mar 8th, 2019 7:49 pm
Scroll